A law firm representing hospitals and other 340B covered entities across the U.S. has called on more than two dozen [...] …
Category: Regulatory
The federal government is likely to continue opposing 340B rebate models even as it moves to resolve four separate contract [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Exclusive
Arkansas Plans to Challenge J&J’s Contested 340B Rebate Proposal for Violation of State Law
Arkansas plans to challenge Johnson & Johnson’s (J&J’s) 340B rebate proposal for violating the state’s law barring drugmaker contract pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The U.S. government is asking a federal district court in Washington, D.C., to rule for drugmakers in four separate lawsuits [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical manufacturer Merck has announced it will refund 340B covered entities for certain overcharges of its inhaler, Proventil HFA, during [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Certain formulations for four of the first ten drugs selected for Medicare drug price negotiations have newly negotiated prices lower [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two major hospital advocacy groups are urging the federal agency that oversees the 340B program to “take immediate enforcement action” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Johnson & Johnson’s (J&J’s) proposed 340B rebate model, which has not received government approval, would give the drugmaker significantly more [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker Kedrion Biopharma has posted a refund notice to 340B providers, and Mylan notified covered entities of National Drug Code [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The federal agency that oversees the 340B program did not approve drugmaker Johnson & Johnson’s (J&J’s) proposal to convert certain [...] …